s6y Marker Therapeutics, Inc. 10-Q

Marker Therapeutics, Inc. 10-Q, filed May 21, 2012: IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS
3 Months Ended
Mar. 31, 2012
RELATED PARTY TRANSACTIONS

Note 8:     Related Party Transactions

During the three months ended March 31, 2012, the Company entered into transactions with certain officers and directors of the Company as follows:

(a) incurred $80,100 (March 31, 2011 - $62,100) in management fees and $22,500 (March 31, 2011 - $22,500) in research and development services paid to officers and directors during the period;

(b) recorded $29,562 (March 31, 2011 - $301,134) in stock based compensation for the fair value of options granted to management that were granted and or vested during the period;

(c) converted $50,000 (March 31, 2011 - $75,000) of debt due to related parties during the period, which were settled with shares.

All related party transactions (other than stock based consideration) involving provision of services were recorded at the exchange amount, which is the amount established and agreed to by the related parties as representing fair value. The Company accounted for the debt settlement transactions with related parties at management’s estimate of fair value, using amounts similar to arm’s length settlements for debt settled.

At March 31, 2012, the Company had amounts owing to directors and officers of $293,805 (December 31, 2011 - $322,905). Amounts due to related parties are unsecured, non-interest bearing and have no specific terms of repayment.